The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Genome-wide genotyping.
- Who it may be relevant to
- Registry conditions: Primary Pulmonary Lymphoepithelioma-like Carcinoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Genetic Susceptibility Study of Primary Pulmonary Lymphoepithelioma-like Carcinoma
Overview
This retrospective case-control study aims to investigate the genetic mechanisms of primary Pulmonary Lymphoepithelioma-like Carcinoma, identify genetic susceptibility loci associated with its onset, and explore potential pathogenic genes, providing new insights for its etiological research.
Detailed description
Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare non-small cell lung cancer (NSCLC) that histologically resembles nasopharyngeal carcinoma (NPC) and predominantly affects the Asian population. Epstein-Barr virus (EBV) infection is a recognized pathogenic factor, and the regional prevalence of pLELC suggests that genetic susceptibility also plays an important role. However, no genetic studies on pLELC have been conducted, leaving its genetic etiology poorly understood. In this study, genotyping for all the subjects was performed by using Illumina Infinium Global Screening Array. Genome-wide association followed by meta-analysis was performed for pLELC cases and healthy controls. The primary objective of this study is to discover susceptibility genes that explain the genetic mechanisms of pLELC.
Interventions
- Genetic Genome-wide genotyping
Whole blood from the participants was used to extract DNA for genotyping.
Primary outcome measures
- the occurrence of Pulmonary Lymphoepithelioma-like Carcinoma [Time frame: The enrollment of the participants]
Eligibility criteria
Case:
Inclusion criteria
The subject is pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma.
Exclusion criteria
The subject is diagnosed with metastatic nasopharyngeal carcinoma; The subject has heavy cardiovascular, liver, or kidney disease.
Controls:
Inclusion criteria
The subject is in good physical condition and has a stable level of consciousness;
Exclusion criteria
The subject has prevalent cancer; The subject has heavy cardiovascular, liver, or kidney disease.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
China · 2 centers
- Foshan First People's Hospital — Foshan
- Sun Yat-sen University Cancer Center — Guangzhou
Identifiers
NCT: NCT06801977 · SL-B2025-059-01